Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Antares Therapeutics has secured $177m in Series A financing round for the development of precision medicines.

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...